Paes Bosco A, Bacchini Fabiana, Bracht Marianne, Rodgers-Gray Barry, Carbonell-Estrany Xavier
Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Canadian Premature Babies Foundation, Toronto, Ontario, Canada.
Hum Vaccin Immunother. 2025 Dec;21(1):2521920. doi: 10.1080/21645515.2025.2521920. Epub 2025 Jun 24.
Respiratory syncytial virus (RSV) remains a leading cause of severe lower respiratory tract infection, hospitalization, morbidity and mortality in young children. This review summarizes current RSV immunization strategies and parental perspectives on their use. Until recently, immunization was limited to high-risk infants and children, including those born prematurely or with significant co-morbidities, monthly dosing with the monoclonal antibody (mAb) palivizumab. Recent approvals of long-acting mAb nirsevimab and the maternal RSV pre-fusion F vaccine combined with other anticipated options such as long-acting mAb clesrovimab, and future pediatric vaccines, signal a shift in RSV immunization. Research studies revealed that consistent education and information on RSV for both, healthcare providers and parents is essential for the immunization program success. We report findings from a survey assessing the level of immunization acceptance among Canadian parents. Provision of education through healthcare professionals, printed materials, parent groups, social media, and the internet were recommended.
呼吸道合胞病毒（RSV）仍然是幼儿严重下呼吸道感染、住院、发病和死亡的主要原因。本综述总结了当前RSV免疫策略以及家长对其使用的看法。直到最近，免疫接种还仅限于高危婴儿和儿童，包括早产或患有严重合并症的儿童，每月注射单克隆抗体（mAb）帕利珠单抗。长效单克隆抗体尼塞韦单抗和母体RSV预融合F疫苗的近期获批，以及其他预期的选择，如长效单克隆抗体克塞罗韦单抗，还有未来的儿科疫苗，都标志着RSV免疫的转变。研究表明，对医疗保健提供者和家长进行一致的RSV教育和信息提供对于免疫计划的成功至关重要。我们报告了一项评估加拿大父母免疫接受程度的调查结果。建议通过医疗专业人员、印刷材料、家长团体、社交媒体和互联网提供教育。
